Ketamine for chronic non‐cancer pain: A meta‐analysis and trial sequential analysis of randomized controlled trials

Ketamine for chronic non‐cancer pain: A meta‐analysis and trial sequential analysis of... IntroductionChronic pain management remains a challenge for physicians (Argoff et al., ; Birklein et al., ; Finnerup et al., ), particularly as available treatments are only modestly effective in reducing pain. According to a recent meta‐analysis on pharmacotherapy for neuropathic pain, the number needed to treat (NNT) for commonly prescribed drugs ranged from 3 to 6 for a defined goal of just 30 to 50% reduction in pain intensity (Finnerup et al., ). Antidepressants (tricyclics, serotonin and norepinephrine reuptake inhibitors), anti‐epileptics (gabapentin, pregabalin) and opioid agents are commonly prescribed drugs. Unfortunately, they are frequently associated with side effects that result in reduced dosages and limited efficacy (Finnerup et al., ). As a consequence, discovering new medications and exploring optimal pharmacological associations are still significant fields of research in chronic pain management.Ketamine, an NMDA antagonist and anaesthetic agent, was first synthesized in 1962 and is still in use today (Iacobucci et al., ). It is commonly employed as an antihyperalgesia agent intraoperatively and perioperatively (Aveline et al., ; Angst and Clark, ; Abrishamkar et al., ). Given that chronic pain pathophysiology involves glutamate receptor activation, and particularly NMDA receptors (Nijs et al., ; Niesters and Dahan, ; Niesters et al., ; Colloca et al., ), many articles have been published over http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png European Journal of Pain Wiley

Ketamine for chronic non‐cancer pain: A meta‐analysis and trial sequential analysis of randomized controlled trials

Loading next page...
 
/lp/wiley/ketamine-for-chronic-non-cancer-pain-a-meta-analysis-and-trial-lGRxdmTMAC
Publisher
Wiley Subscription Services, Inc., A Wiley Company
Copyright
Copyright © 2018 European Pain Federation ‐ EFIC®
ISSN
1090-3801
eISSN
1532-2149
D.O.I.
10.1002/ejp.1153
Publisher site
See Article on Publisher Site

Abstract

IntroductionChronic pain management remains a challenge for physicians (Argoff et al., ; Birklein et al., ; Finnerup et al., ), particularly as available treatments are only modestly effective in reducing pain. According to a recent meta‐analysis on pharmacotherapy for neuropathic pain, the number needed to treat (NNT) for commonly prescribed drugs ranged from 3 to 6 for a defined goal of just 30 to 50% reduction in pain intensity (Finnerup et al., ). Antidepressants (tricyclics, serotonin and norepinephrine reuptake inhibitors), anti‐epileptics (gabapentin, pregabalin) and opioid agents are commonly prescribed drugs. Unfortunately, they are frequently associated with side effects that result in reduced dosages and limited efficacy (Finnerup et al., ). As a consequence, discovering new medications and exploring optimal pharmacological associations are still significant fields of research in chronic pain management.Ketamine, an NMDA antagonist and anaesthetic agent, was first synthesized in 1962 and is still in use today (Iacobucci et al., ). It is commonly employed as an antihyperalgesia agent intraoperatively and perioperatively (Aveline et al., ; Angst and Clark, ; Abrishamkar et al., ). Given that chronic pain pathophysiology involves glutamate receptor activation, and particularly NMDA receptors (Nijs et al., ; Niesters and Dahan, ; Niesters et al., ; Colloca et al., ), many articles have been published over

Journal

European Journal of PainWiley

Published: Jan 1, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off